All In Biotech

Drug Trial Radar · NCT06835504

Morphine or Ketamine for Analgesia

Efficacy of Intravenous Sub-Dissociative Ketamine Versus Intravenous Morphine in Children With Acute Pain

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,010 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,010

Planned (sponsor's estimate)

Start

Oct 17, 2026

Primary completion

Apr 23, 2030

Study completion Apr 23, 2030

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.

Conditions

  • Abdominal Pain
  • Isolated Extremity Fracture
  • Pain
  • Pediatrics

Interventions

  • Ketamine hydrochlorideDrug

    Sub-dissociative ketamine, IV

  • Morphine sulphateDrug

    Morphine, IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain intensityTime frame: Up to 240 minutes after completion of study drug administration or until a terminal event occurs
  2. Cardiopulmonary adverse events requiring an interventionTime frame: Up to 120 minutes after completion of study drug administration or until a terminal event occurs
  3. Pain-related functionTime frame: Days 1, 2,3, and 7 after discharge.
  4. Post-traumatic stressTime frame: Baseline (at time of enrollment) and days 7, 30, 90 and 180 after discharge.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California · Not yet recruiting

  • UC Davis Children's Hospital

    Sacramento, California · Recruiting

  • Nemours Children's Hospital

    Wilmington, Delaware · Recruiting

  • Arthur M. Blank Hospital

    Atlanta, Georgia · Not yet recruiting

  • NewYork Presbyterian Morgan Stanley Children's Hospital

    New York, New York · Not yet recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Children's Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.